XenoGesis were crowned winners of the Export Achievement Award at the 2019 Medilink East Midlands Business Awards Ceremony.
XenoGesis won the Export Achievement Award, sponsored by Morningside Pharmaceuticals, in recognition of the company’s 78% increase in exports. In the financial year ending March 2019, 50% of all its revenue came from overseas clients, a trend that has continued.
Richard Weaver, CEO at XenoGesis, said: “We are delighted to have won the Export Achievement award in acknowledgement of the hard work of the XenoGesis team. Exports are a massive part of our business and together we have developed a world-class DMPK offering and are continually re-investing our profits into company development and infrastructure.”
The annual awards recognise organisations in the life science sector who in the past year have excelled in different areas, including Start-up, Export, Delivering Innovation in to Health and Care, Innovation and Outstanding Achievement. This year’s awards also saw two new categories – One to Watch and Deal of the Year. Over 200 members of the East Midlands life sciences community attended the event to celebrate and reflect on the past year.
XenoGesis has now been shortlisted for the Medilink UK Healthcare Business Awards, with the chance of being crowned national winners at a ceremony set to take place on 1 April 2020 at the NEC in Birmingham.
Dr Darren Clark, Chief Executive, Medilink East Midlands, said: “It’s great to see so many exciting life science industry developments coming out of the East Midlands. All our winning companies have demonstrated a high level of expertise and are extremely worthy winners. I’d like to thank the awards sponsors who continue to show their support to Medilink EM and the companies we work with.”
For more information, and to read about the 2019 winners, visit the Medilink East Midlands website.